1. 1396PEfficacy and safety of crizotinib in previously treated patients (Pts) with ALK+ advanced non-small cell lung cancer (NSCLC) aged ≥65 years (y). (23rd October 2018) Authors: Moro-Sibilot, D; Ahn, M-J; Halmos, B; Kim, D-W; Riely, G J; Shaw, A T; Yang, P-C; Lanzalone, S; Polli, A; Wilner, K D; De Castro Carpeño, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1397PLong-term safety of crizotinib in previously treated patients (pts) with ALK-positive advanced/metastatic non-small cell lung cancer (NSCLC). (23rd October 2018) Authors: Crinò, L; Ahn, M-J; Han, J-Y; Liu, X; Ou, S-H I; Shaw, A T; Yang, P-C; Shi, Y-K; Lanzalone, S; Polli, A; Wilner, K D; Kim, D-W Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 480PSafety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050. (24th November 2019) Authors: Mok, T S K; Cheng, Y; Zhou, X; Lee, K H; Nakagawa, K; Niho, S; Rosell, R; Linke, R; Wong, C H; Tang, Y; Singh, M; Wilner, K D; Wu, Y-L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer. (13th July 2018) Authors: Soria, J -C; Ho, S N; Varella-Garcia, M; Iafrate, A J; Solomon, B J; Shaw, A T; Blackhall, F; Mok, T S; Wu, Y -L; Pestova, K; Wilner, K D; Polli, A; Paolini, J; Lanzalone, S; Green, S; Camidge, D R Journal: Annals of oncology Issue: Volume 29:Number 9(2018) Page Start: 1964 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. LBA19Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations. (24th November 2019) Authors: Mok, T S K; Cheng, Y; Zhou, X; Lee, K H; Nakagawa, K; Niho, S; Linke, R; Rosell, R; Corral, J; Migliorino, M R; Pluzanski, A; Noonan, K; Tang, Y; Wilner, K D; Wu, Y-L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗